1
|
Huang C, Xu S, Luo Z, Li D, Wang R, Wang T. Epidemiological Evidence Between Variants in Matrix Metalloproteinases-2, -7, and -9 and Cancer Risk. Front Oncol 2022; 12:856831. [PMID: 35574300 PMCID: PMC9095957 DOI: 10.3389/fonc.2022.856831] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 03/31/2022] [Indexed: 12/31/2022] Open
Abstract
Background Matrix metalloproteinases (MMPs), a kind of proteases, have a critical function in cancer occurrence, invasion, and migration. MMP gene variants (e.g., MMP-2, MMP-7, and MMP-9) can affect the biological functions of these enzymes and lead to the occurrence and progression of cancer, which has become a hot topic in recent years, but the corresponding results are still controversial. In this context, here, the meta-analysis was conducted for assessing the relations of variants in MMP-2, MMP-7, and MMP-9 with the risk of various cancers. Methods PubMed, Web of Science, and Medline were systemically searched, and data were extracted from all eligible studies so as to investigate the susceptibility of MMP-2, MMP-7, and MMP-9 to different types of cancers. The association between a variant in MMP and cancer susceptibility was analyzed through odds ratios (ORs) as well as 95% CIs. The Venice criteria and false-positive report probability (FPRP) were adopted to evaluate epidemiological evidence of significant associations discovered. Results The associations between the variants of MMPs and cancer risk in 36,530 cases and 41,258 controls were found, with 12 associations (MMP-2 rs243865 with esophageal cancer and lung cancer, MMP-7 rs11568818 with bladder and cervical cancer, and MMP-9 rs3918242 with breast cancer) rated as strong associations for cancer risk and 7 and 15 as moderate and weak associations, respectively. These significant associations were mostly found in Asians. Conclusions These findings support the relations between variants of MMP-2, MMP-7, and MMP-9 and various cancers risk, demonstrating the credibility of these relations.
Collapse
Affiliation(s)
- Chenglu Huang
- Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Suqin Xu
- Department of Radiology, Chongqing University Cancer Hospital, Chongqing, China
| | - Zhilin Luo
- Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Dong Li
- Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Rui Wang
- Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Tianhu Wang
- Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
| |
Collapse
|
2
|
Scherer D, Deutelmoser H, Balavarca Y, Toth R, Habermann N, Buck K, Kap EJ, Botma A, Seibold P, Jansen L, Lorenzo Bermejo J, Weigl K, Benner A, Hoffmeister M, Ulrich A, Brenner H, Burwinkel B, Chang-Claude J, Ulrich CM. Polymorphisms in the Angiogenesis-Related Genes EFNB2, MMP2 and JAG1 Are Associated with Survival of Colorectal Cancer Patients. Int J Mol Sci 2020; 21:E5395. [PMID: 32751332 PMCID: PMC7432124 DOI: 10.3390/ijms21155395] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 07/21/2020] [Accepted: 07/22/2020] [Indexed: 12/24/2022] Open
Abstract
An individual's inherited genetic variation may contribute to the 'angiogenic switch', which is essential for blood supply and tumor growth of microscopic and macroscopic tumors. Polymorphisms in angiogenesis-related genes potentially predispose to colorectal cancer (CRC) or affect the survival of CRC patients. We investigated the association of 392 single nucleotide polymorphisms (SNPs) in 33 angiogenesis-related genes with CRC risk and survival of CRC patients in 1754 CRC cases and 1781 healthy controls within DACHS (Darmkrebs: Chancen der Verhütung durch Screening), a German population-based case-control study. Odds ratios and 95% confidence intervals (CI) were estimated from unconditional logistic regression to test for genetic associations with CRC risk. The Cox proportional hazard model was used to estimate hazard ratios (HR) and 95% CIs for survival. Multiple testing was adjusted for by a false discovery rate. No variant was associated with CRC risk. Variants in EFNB2, MMP2 and JAG1 were significantly associated with overall survival. The association of the EFNB2 tagging SNP rs9520090 (p < 0.0001) was confirmed in two validation datasets (p-values: 0.01 and 0.05). The associations of the tagging SNPs rs6040062 in JAG1 (p-value 0.0003) and rs2241145 in MMP2 (p-value 0.0005) showed the same direction of association with overall survival in the first and second validation sets, respectively, although they did not reach significance (p-values: 0.09 and 0.25, respectively). EFNB2, MMP2 and JAG1 are known for their functional role in angiogenesis and the present study points to novel evidence for the impact of angiogenesis-related genetic variants on the CRC outcome.
Collapse
Affiliation(s)
- Dominique Scherer
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
- Institute of Medical Biometry and Informatics, University of Heidelberg, 69117 Heidelberg, Germany;
| | - Heike Deutelmoser
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
- Institute of Medical Biometry and Informatics, University of Heidelberg, 69117 Heidelberg, Germany;
| | - Yesilda Balavarca
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
| | - Reka Toth
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
- Division of Cancer Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany
| | - Nina Habermann
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
- European Molecular Biology Laboratory (EMBL), Genome Biology, 69117 Heidelberg, Germany
| | - Katharina Buck
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
| | - Elisabeth Johanna Kap
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (E.J.K.); (P.S.); (J.C.-C.)
| | - Akke Botma
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (E.J.K.); (P.S.); (J.C.-C.)
| | - Petra Seibold
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (E.J.K.); (P.S.); (J.C.-C.)
| | - Lina Jansen
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (L.J.); (K.W.); (M.H.)
| | - Justo Lorenzo Bermejo
- Institute of Medical Biometry and Informatics, University of Heidelberg, 69117 Heidelberg, Germany;
| | - Korbinian Weigl
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (L.J.); (K.W.); (M.H.)
| | - Axel Benner
- Division of Biostatistics, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany;
| | - Michael Hoffmeister
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (L.J.); (K.W.); (M.H.)
| | - Alexis Ulrich
- Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, 69117 Heidelberg, Germany;
- Chirurgische Klinik I, Lukaskrankenhaus Neuss, 41464 Neuss, Germany
| | - Hermann Brenner
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (L.J.); (K.W.); (M.H.)
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany
| | - Barbara Burwinkel
- Division of Molecular Epidemiology, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany;
- Division Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, 69117 Heidelberg, Germany
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (E.J.K.); (P.S.); (J.C.-C.)
- Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Cornelia M. Ulrich
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany; (D.S.); (H.D.); (Y.B.); (R.T.); (N.H.); (K.B.); (A.B.); (H.B.)
- Huntsman Cancer Institute, Salt Lake City, UT 84112, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT 84112, USA
| |
Collapse
|
3
|
Lin L, Xu W, Zhang G, Ren P, Zhao J, Yan Q. Association of interleukin-22 polymorphisms with the colon cancer: A case-control study. Immunol Lett 2017; 188:59-63. [PMID: 28624523 DOI: 10.1016/j.imlet.2017.06.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2017] [Revised: 06/12/2017] [Accepted: 06/12/2017] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Interleukin-22 (IL-22), an IL-10 family cytokine produced by T cells and innate lymphoid cells, is implicated in inflammation and tumorigenesis. In this study, we aimed to investigate the association of IL-22 polymorphisms with the colon cancer in a Chinese population. MATERIALS AND METHODS Five hundred forty colon cancer cases and 540 healthy controls were recruited in the case-control study. The fluorogenic 5' exonuclease assays were used for genotype analysis of three common polymorphisms (-429C/T, +1046T/A and +1995A/C) of the IL-22 gene. RESULTS Colon cancer cases had a significantly higher frequency of IL-22-429 TT genotype [odds ratio (OR)=1.69, 95% confidence interval (CI)=1.24, 2.30; P=0.001] and -429T allele (OR=1.35, 95% CI=1.14, 1.60; P=0.001) than healthy controls. The findings are still emphatic by the Bonferroni correction (P<0.017). When stratifying by the differentiation of colon cancer, we found that colon cancer cases with poor differentiation had a significantly higher frequency of IL-22-429 TT genotype (OR=1.45, 95% CI=1.02, 2.07; P=0.04). When stratifying by the tumor location, tumor size, growth pattern and TNM stage of colon cancer, we found no statistical association. The IL-22 +1046T/A and IL-22 +1995A/C gene polymorphisms were not associated with colon cancer. CONCLUSION Our findings suggested that the IL-22 -429C/T gene polymorphisms might be associated with colon cancer.
Collapse
Affiliation(s)
- Lin Lin
- Department of Colorectal Anal Surgery, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Weili Xu
- Department of Colorectal Anal Surgery, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Guojian Zhang
- Department of Colorectal Anal Surgery, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Pengtao Ren
- Department of Colorectal Anal Surgery, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Jing Zhao
- Department of Colorectal Anal Surgery, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Qinghui Yan
- Department of Colorectal Anal Surgery, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
| |
Collapse
|
4
|
Sanromán-Iglesias M, Lawrie CH, Liz-Marzán LM, Grzelczak M. Nanoparticle-Based Discrimination of Single-Nucleotide Polymorphism in Long DNA Sequences. Bioconjug Chem 2017; 28:903-906. [DOI: 10.1021/acs.bioconjchem.7b00028] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- María Sanromán-Iglesias
- CIC biomaGUNE, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain
- Oncology
Area, Biodonostia Research Institute, 20014 Donostia-San
Sebastián, Spain
| | - Charles H. Lawrie
- Oncology
Area, Biodonostia Research Institute, 20014 Donostia-San
Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Luis M. Liz-Marzán
- CIC biomaGUNE, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, 20014 Donostia-San
Sebastián, Spain
| | - Marek Grzelczak
- CIC biomaGUNE, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, 20014 Donostia-San
Sebastián, Spain
| |
Collapse
|
5
|
Banday MZ, Sameer AS, Mir AH, Mokhdomi TA, Chowdri NA, Haq E. Matrix metalloproteinase (MMP) -2, -7 and -9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population - A case-control study and a mini review. Gene 2016; 589:81-89. [PMID: 27222481 DOI: 10.1016/j.gene.2016.05.028] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2016] [Revised: 04/12/2016] [Accepted: 05/17/2016] [Indexed: 12/11/2022]
Abstract
Matrix metalloproteinases (MMPs) are proteolytic enzymes that play a pivotal role in the transformation and progression of tumors at all stages, especially during the invasion and metastasis. The aim of this study was to determine the genetic association of MMP2, MMP7 and MMP9 promoter polymorphisms with colorectal cancer (CRC) susceptibility and development risk in ethnic Kashmiri population. The genotype frequencies of MMP2-1306C/T, MMP7-181A/G and MMP9-1562C/T SNPs were compared between 142 CRC patients and 184 healthy controls by using PCR-RFLP method. The association between all the three MMP promoter polymorphisms and the modulation of risk of CRC was found to be significant (p≤0.05). The heterozygous genotype (CT) of MMP2-1306C/T SNP and variant genotype (GG) of MMP7-181A/G SNP showed a significant association with decreased risk for the development of CRC [OR, 0.61 (95%CI, 0.37-1.01); p=0.05 and OR, 0.43 (95%CI, 0.20-0.90); p=0.02, respectively] whereas the heterozygous genotype (CT) of MMP9-1562C/T SNP showed a significant association with increased risk for the development of colorectal cancer [OR, 1.88 (95%CI, 1.11-3.18); p=0.02]. Further, the less common MMP9-1562T allele was found to be significantly associated with an increased risk of colorectal cancer [OR, 1.74 (95%CI, 1.15-2.62); p=0.007]. Our results suggest that these MMP2, MMP7 and MMP9 promoter polymorphisms play a role as one of the key modulators of the risk of developing colorectal cancer in Kashmiri population.
Collapse
Affiliation(s)
- Mujeeb Zafar Banday
- Department of Biotechnology, University of Kashmir, Hazratbal, Srinagar, Kashmir, India
| | - Aga Syed Sameer
- Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Ashaq Hussain Mir
- Department of Biotechnology, University of Kashmir, Hazratbal, Srinagar, Kashmir, India
| | - Taseem A Mokhdomi
- Department of Biotechnology, University of Kashmir, Hazratbal, Srinagar, Kashmir, India
| | - Nissar A Chowdri
- Department of Surgery, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, India
| | - Ehtishamul Haq
- Department of Biotechnology, University of Kashmir, Hazratbal, Srinagar, Kashmir, India.
| |
Collapse
|
6
|
SAVASOGLU K, EMIN ERDAL M. Association of MMP-2 (-1306 C>T), MMP-9 (-1562 C>T) Gene Polymorphism and the Formation of the Hematological Malignancies. IRANIAN JOURNAL OF PUBLIC HEALTH 2016; 45:392-3. [PMID: 27141505 PMCID: PMC4851757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Kaan SAVASOGLU
- Dept. of Medical Genetics, İzmir Katip Çelebi University, Atatürk Education and Research Hospital, İzmir, Turkey,Corresponding Author:
| | - Mehmet EMIN ERDAL
- Dept. of Medical Biology, Mersin University School of Medicine, Mersin, Turkey
| |
Collapse
|
7
|
Chen J, Yang P, Yang J, Wen Z, Zhang B, Zheng X. GIT1 is a novel prognostic biomarker and facilitates tumor progression via activating ERK/MMP9 signaling in hepatocellular carcinoma. Onco Targets Ther 2015; 8:3731-42. [PMID: 26719701 PMCID: PMC4689273 DOI: 10.2147/ott.s96715] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Aim Multiple studies have revealed that G-protein-coupled receptor kinase-interacting protein 1 (GIT1) is overexpressed in many cancers and facilitates tumor progression. However, the role of GIT1 in hepatocellular carcinoma (HCC) remains unclear. Methods GIT1 expression was detected in cell lines and 130 pairs of HCC and matched adjacent noncancerous samples. Transwell assay, flow cytometry, caspase 3/7 activity assay, 5-bromodeoxyuridine cell proliferation assay, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay were used to assess invasion, migration, apoptosis, and proliferation of HCC cells. Furthermore, GIT1 expression was detected by immunohistochemistry to evaluate its correlation with phospho-extracellular signal-regulated kinase (p-ERK)1/2. The regulatory effect of GIT1 on ERK1/2, p-ERK1/2, and matrix metalloproteinase-9 (MMP9) in HCC cells was confirmed by immunoblotting. Results In this study, we demonstrated that GIT1 was more highly expressed in HCC samples than that in non-HCC samples, and overexpression of GIT1 was correlated with clinicopathological features of poor prognosis. Clinical analysis demonstrated that GIT1 is an independent prognostic biomarker for predicting overall survival and disease-free survival of patients with HCC. In vitro studies showed that downregulation of GIT1 facilitated HCC cell apoptosis and repressed HCC cell invasion, migration, and proliferation. Overexpression of GIT1 is associated with p-ERK1/2 amplification in HCC tissues. Moreover, downregulation of GIT1 resulted in inactivation of ERK signaling and downregulation of MMP9. Conclusion Our findings indicate that GIT1 is an independent prognostic biomarker and facilitates HCC progression via activating ERK/MMP9 signaling.
Collapse
Affiliation(s)
- Junyi Chen
- Department of General Surgery, Branch of the First People's Hospital of Shanghai, People's Republic of China
| | - Pinghua Yang
- Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, People's Republic of China
| | - Jue Yang
- Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, People's Republic of China
| | - Zhijian Wen
- Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, People's Republic of China
| | - Baohua Zhang
- Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, People's Republic of China
| | - Xin Zheng
- Department of General Surgery, Branch of the First People's Hospital of Shanghai, People's Republic of China ; Department of Traditional Chinese Medicine, Branch of the first People's Hospital of Shanghai, Shanghai, People's Republic of China
| |
Collapse
|
8
|
Jiang QH, Peng HX, Zhang Y, Tian P, Xi ZL, Chen H. rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population. Onco Targets Ther 2015; 8:3041-5. [PMID: 26543374 PMCID: PMC4622418 DOI: 10.2147/ott.s89746] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
rs712 within 3'-untranslated region of KRAS can affect the specific binding between the mRNA and its targeted microRNAs, leading to the activation of KRAS oncogene. However, the possible association between the locus and susceptibility to colorectal cancer (CRC) remains unclear. We investigated genotypes of the locus in 586 cases and 476 controls to explore the possible association between them. Results of our case-control study showed that genotypes TT (6.5% vs 2.5%, P=0.002, adjusted odds ratio [OR] =2.810, 95% confidence interval [CI] =1.342-5.488) and GT/TT (36.5% vs 30.5%, P=0.038, adjusted OR =1.342, 95% CI =1.030-1.712) and allele T (21.5% vs 6.5%, P=0.004, adjusted OR =1.328, 95% CI =1.105-1.722) of rs712 were significantly associated with an increased risk of CRC, and the significant association was also observed in the recessive model (TT vs GG/GT, 6.5% vs 2.5%, P=0.003, adjusted OR =0.372, 95% CI =0.191-0.725). However, there was no association between genotype GT and risk of CRC (30.0% vs 28.0%, P=0.235, adjusted OR =1.210, 95% CI =0.903-1.548). Furthermore, genotype GT (P=0.003) and allele T (P=0.003) were significantly associated with poor differentiation, and genotypes GT and TT and allele T were significantly associated with tumor-node-metastases stage III (P=0.001 for GT vs GG, P<0.001 for TT vs GG, and P<0.001 for T vs G) and node metastasis (P<0.001 for GT vs GG, P=0.001 for TT vs GG, and P<0.001 for T vs G), respectively. These findings indicated that allele T and genotypes TT and GT/TT of rs712 might be susceptible factors for CRC, and mutated allele and genotypes of the locus might predict a poor clinical outcome in Chinese population.
Collapse
Affiliation(s)
- Qiang-Hua Jiang
- Department of Surgery, Dongyang People’s Hospital, Dongyang, Zhejiang, People’s Republic of China
| | - Hong-Xin Peng
- Medical College, Southeast University, Nanjing, Jiangsu, People’s Republic of China
- Central Laboratory, Nanjing First Hospital, Nanjing, Jiangsu, People’s Republic of China
| | - Yi Zhang
- Hubei Key Laboratory of Biological Targeted Therapy, Yichang Yiling Hospital, Yichang, Hubei, People’s Republic of China
| | - Peng Tian
- Hubei Key Laboratory of Biological Targeted Therapy, Yichang Yiling Hospital, Yichang, Hubei, People’s Republic of China
| | - Zu-Lian Xi
- Hubei Key Laboratory of Biological Targeted Therapy, Yichang Yiling Hospital, Yichang, Hubei, People’s Republic of China
| | - Hao Chen
- Hubei Key Laboratory of Biological Targeted Therapy, Yichang Yiling Hospital, Yichang, Hubei, People’s Republic of China
| |
Collapse
|